Localized Unresectable Adult Primary Liver Cancer
34
0
2
21
Key Insights
Highlights
Success Rate
70% trial completion
Published Results
14 trials with published results (41%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
26.5%
9 terminated out of 34 trials
70.0%
-16.5% vs benchmark
0%
0 trials in Phase 3/4
67%
14 of 21 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 21 completed trials
Clinical Trials (34)
TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer
Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery
3-Tesla MRI Response to TACE in HCC (Liver Cancer)
Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery
Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder
Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer
Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers
AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer
Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer
Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer
Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery